The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
Open accessPublished version of a preprint
Abstract
Polymeric micelle formulation of an immune modulator improves survival in a highly aggressive model of non–small cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequently employed combinations are 1) a combination of several chemotherapies for killing cancer cells, 2) a combination of chemotherapy with additional agents, such as tumor microenvironment modifiers, or more recently 3) a combination of immunotherapy with anticancer agents [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The latest study highlighted that even the best combinations of the chemotherapeutic agents determined in vitro as having the most potent and highly synergistic effect against non-small cell lung cancer (NSCLC) cells may not be effective against the in vivo tumor even at the MTD of those combinations [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, resiquimod, an imidazoquinoline TLR 7/8 agonist, solubilized in POx block copolymer (PMeOx-b-PBuOx-b-PMeOx) micelles had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti-PD1 immune checkpoint blockade therapy as well as platinum-based chemotherapy, which is the mainstay of treatment for NSCLC.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Investigation of the in vivo immune status following resiquimod in polymeric micelles treatment showed that resiquimod-based stimulation of antigen-presenting cells in the tumor microenvironment resulted in the mobilization of anti-tumor CD8+ immune response [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Certain cancers overexpress PD-L1 to benefit from PD-1/PD-L1 axis–mediated suppression of adaptive immunity (3).”
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“4 of 12 of Chou and Talalay, which states that a CI value of less than 1 represents synergy, whereas a CI value greater than 1 indicates antagonism (24).”
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“IL-6 signaling is again pivotal to the differentiation of T and B cells (30).”
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“However, the initial response to cisplatin is often short-lived because of the development of drug resistance (17).”
Non-small-cell lung cancers: a heterogeneous set of diseases
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3775 · Cited by 1,942 · cited 2×
“Nevertheless, the benefits of such interventions are often transient due to the development of chemoresistance, which primarily stems from tumor-host cell interactions (1).”
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 1×
“(55) showed both IL-1 and IL-6 (implicated as a key driver of cytokine storm) were involved in the pathogenesis of cytokine storm in a humanized mouse model of leukemia, and because IL-1 signaling preceded IL-6, the blockade of IL-1 receptor was shown to successfully overcome the toxicities associated with the syndrom…”
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Yang, J., Zhang, L., Yu, C., Yang, X.-F., & Wang, H. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-1 · Cited by 1,099 · cited 1×
“Ly6C+ monocytes are prone to differentiate into inflammatory macrophages and secrete TH1 cytokines that activate adaptive immune response (38).”
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Self-citationDecoding Toll-like receptors: Recent insights and perspectives in innate immunity
Kawai, T., Ikegawa, M., Ori, D., & Akira, S. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.004 · Cited by 528
Bhagchandani, S., Johnson, J. A., & Irvine, D. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.013 · Cited by 188
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Sun, H., Li, Y., Zhang, P., Xing, H., Zhao, S. Q., Song, Y., Wan, D., & Yu, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00436-7 · Cited by 166
“Another study showed that R848-based stimulation of APCs in the tumor microenvironment resulted in the mobilization of an antitumor CD8+ immune response for treating metastatic NSCLC [70].”
BackgroundInfluentialZahoranová, A., & Luxenhofer, R. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001382 · Cited by 117
Metadata
- Authors
- Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA.
- Corresponding author
- Pecot, Chad V.
- Kabanov, Alexander V.
- ORCID
- Venue
- Science Advances
- Published
- 2020-06-17
- Volume
- 6
- Issue
- 25
- Pages
- eaba5542-eaba5542
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7299629
- OpenAlex
- W3036026766
- Cited by
- 63
- References
- 64
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 20 · 2021: 18 · 2020: 2
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by-nc)
- UNC Libraries
- Funders
- National Institutes of Health (5U54CA198999-05)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- poly(2-oxazoline), resiquimod, TLR7/8 agonist, lung adenocarcinoma, metastatic non-small cell lung cancer, drug formulation, survival, cancer immunotherapy
- MeSH terms
- Adenocarcinoma of Lung, Adjuvants, Immunologic, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Oxazoles, Toll-Like Receptor 7, Toll-Like Receptor 8, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. https://app.cochat.ai/papers/10.1126/sciadv.aba5542
- The paper
- Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V. (2020). High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. Science Advances. https://doi.org/10.1126/sciadv.aba5542
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.